Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial-Reference-Cited by-同舟云学术

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Published:2018-12 Issue:12 Volume:19 Page:1641-1653
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Trudel Suzanne,Lendvai Nikoletta,Popat Rakesh,Voorhees Peter M,Reeves Brandi,Libby Edward N,Richardson Paul G,Anderson Larry D,Sutherland Heather J,Yong Kwee,Hoos Axel,Gorczyca Michele M,Lahiri Soumi,He Zangdong,Austin Daren J,Opalinska Joanna B,Cohen Adam D

Funder

National Institutes of Health Cancer Center Support

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study;Kumar;Leukemia,2017

2. Regulated expression of BAFF-binding receptors during human B cell differentiation;Darce;J Immunol,2007

3. BCMA is essential for the survival of long-lived bone marrow plasma cells;O'Connor;J Exp Med,2004

4. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma;Lee;Br J Haematol,2016

5. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma;Sanchez;Clin Cancer Res,2016

Cited by 207 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial;Blood Cancer Journal;2024-09-11

2. Strategies for successful dose optimization in oncology drug development: a practical guide;Journal of Biopharmaceutical Statistics;2024-08-11

3. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies;The Oncologist;2024-07-24

4. Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?;Journal of Ocular Pharmacology and Therapeutics;2024-07-08

5. Rediscovering hemostasis abnormalities in multiple myeloma: The new era;Heliyon;2024-07